An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
Date: November 30, 2020
Issue #:
1612Summary:
The investigational neutralizing IgG1 monoclonal
antibody bamlanivimab (LY-CoV555; Lilly) has
been granted an FDA Emergency Use Authorization
(EUA) for treatment of recently diagnosed mild
to moderate COVID-19 in patients who are ≥12
years old, weigh at least 40 kg, and are at high
risk for progressing to severe disease and/or
hospitalization (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research